Racotumomab

Personalis, Inc. Publishes New Data Demonstrating a Novel Composite Biomarker NEOPS™ for Predicting Response to Cancer Immunotherapy in Late-Stage Melanoma Patients

Retrieved on: 
Monday, August 2, 2021

The study details the development of the Personalis Neoantigen Presentation Score (NEOPS), a novel composite biomarker for predicting response to cancer immunotherapy.

Key Points: 
  • The study details the development of the Personalis Neoantigen Presentation Score (NEOPS), a novel composite biomarker for predicting response to cancer immunotherapy.
  • Enabled by comprehensive tumor immunogenomic profiling from the Personalis NeXT Platform, NEOPS simultaneously models both neoantigen burden and immune-related resistance mechanisms to better predict immunotherapy response in a cohort of late-stage melanoma patients.
  • In this study, NEOPS was more strongly predictive of therapy response than other standard single analyte and investigational biomarkers tested, including tumor mutational burden.
  • Performance of this composite biomarker was initially tested on a cohort of late-stage melanoma patients receiving immune checkpoint blockade therapies and later validated on an independent dataset of similarly treated late-stage melanoma patients.

Achilles Therapeutics Details Phase I/IIa Clinical Trial Design of CHIRON in Patients with Advanced Non-Small Cell Lung Cancer at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Friday, June 4, 2021

The poster presentation given by Dr Mariam Jamal-Hanjani, scientific investigator for CHIRON and Medical Oncologist from the Cancer Research UK Lung Cancer Centre of Excellence, highlights the design of the ongoing phase I/IIa CHIRON clinical trial evaluating clonal neoantigen T cells (cNeT) in patients with advanced non-small cell lung cancer (NSCLC).

Key Points: 
  • The poster presentation given by Dr Mariam Jamal-Hanjani, scientific investigator for CHIRON and Medical Oncologist from the Cancer Research UK Lung Cancer Centre of Excellence, highlights the design of the ongoing phase I/IIa CHIRON clinical trial evaluating clonal neoantigen T cells (cNeT) in patients with advanced non-small cell lung cancer (NSCLC).
  • Additional data evaluating cNeT persistence, phenotype, and functionality will be reviewed while also exploring potential biomarkers of clinical activity and factors affecting response.
  • This will include analysis of patient samples using a bespoke plasma ctDNA assay.
  • The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma.

Achilles Therapeutics doses first patient in Phase I/II Study in advanced non-small cell lung cancer

Retrieved on: 
Tuesday, June 23, 2020

Stevenage, UK 23 June 2020 Achilles Therapeutics (Achilles), a clinical stage biopharmaceutical company developing personalised cancer immunotherapies, today announced that it has dosed the first patient in a Phase I/II CHIRON study of a clonal neoantigen T cell (cNeT) therapy in patients with advanced non-small cell lung cancer (NSCLC).

Key Points: 
  • Stevenage, UK 23 June 2020 Achilles Therapeutics (Achilles), a clinical stage biopharmaceutical company developing personalised cancer immunotherapies, today announced that it has dosed the first patient in a Phase I/II CHIRON study of a clonal neoantigen T cell (cNeT) therapy in patients with advanced non-small cell lung cancer (NSCLC).
  • In May 2020, Achilles dosed the first patient with cNeT in its Phase I/II THETIS study in recurrent or metastatic malignant melanoma.
  • The Company has two ongoing Phase I/II studies, the THETIS study in patients with recurrent or metastatic malignant melanoma and the CHIRON study in patients with advanced non-small cell lung cancer (NSCLC).
  • Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of all cases.

Achilles Therapeutics doses first patient in Phase I/II Study in advanced non-small cell lung cancer

Retrieved on: 
Tuesday, June 23, 2020

Stevenage, UK 23 June 2020 Achilles Therapeutics (Achilles), a clinical stage biopharmaceutical company developing personalised cancer immunotherapies, today announced that it has dosed the first patient in a Phase I/II CHIRON study of a clonal neoantigen T cell (cNeT) therapy in patients with advanced non-small cell lung cancer (NSCLC).

Key Points: 
  • Stevenage, UK 23 June 2020 Achilles Therapeutics (Achilles), a clinical stage biopharmaceutical company developing personalised cancer immunotherapies, today announced that it has dosed the first patient in a Phase I/II CHIRON study of a clonal neoantigen T cell (cNeT) therapy in patients with advanced non-small cell lung cancer (NSCLC).
  • In May 2020, Achilles dosed the first patient with cNeT in its Phase I/II THETIS study in recurrent or metastatic malignant melanoma.
  • The Company has two ongoing Phase I/II studies, the THETIS study in patients with recurrent or metastatic malignant melanoma and the CHIRON study in patients with advanced non-small cell lung cancer (NSCLC).
  • Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of all cases.

Achilles Therapeutics doses first patient in Phase I/II Study in recurrent or metastatic malignant melanoma

Retrieved on: 
Friday, May 29, 2020

Stevenage, UK 29 May 2020 Achilles Therapeutics (Achilles), a clinical stage biopharmaceutical company developing personalised cancer immunotherapies, today announced that it has dosed the first patient in a Phase I/II study of a clonal neoantigen T cell (cNeT) therapy in patients with recurrent or metastatic malignant melanoma.

Key Points: 
  • Stevenage, UK 29 May 2020 Achilles Therapeutics (Achilles), a clinical stage biopharmaceutical company developing personalised cancer immunotherapies, today announced that it has dosed the first patient in a Phase I/II study of a clonal neoantigen T cell (cNeT) therapy in patients with recurrent or metastatic malignant melanoma.
  • The THETIS study is an open-label, multi-centre Phase I/II trial evaluating the safety, tolerability and clinical efficacy of cNeT therapy as a single dose in patients with recurrent or metastatic malignant melanoma.
  • The dosing of our first melanoma patient with a cell therapy to specifically target all cancer cells, marks a significant milestone in delivering the first precision TIL therapy.
  • Achilles uses its proprietary process to manufacture T cells (cNeT) which exquisitely target a specific set of clonal neoantigens in each patient.

Achilles Therapeutics doses first patient in Phase I/II Study in recurrent or metastatic malignant melanoma

Retrieved on: 
Friday, May 29, 2020

Stevenage, UK 29 May 2020 Achilles Therapeutics (Achilles), a clinical stage biopharmaceutical company developing personalised cancer immunotherapies, today announced that it has dosed the first patient in a Phase I/II study of a clonal neoantigen T cell (cNeT) therapy in patients with recurrent or metastatic malignant melanoma.

Key Points: 
  • Stevenage, UK 29 May 2020 Achilles Therapeutics (Achilles), a clinical stage biopharmaceutical company developing personalised cancer immunotherapies, today announced that it has dosed the first patient in a Phase I/II study of a clonal neoantigen T cell (cNeT) therapy in patients with recurrent or metastatic malignant melanoma.
  • The THETIS study is an open-label, multi-centre Phase I/II trial evaluating the safety, tolerability and clinical efficacy of cNeT therapy as a single dose in patients with recurrent or metastatic malignant melanoma.
  • The dosing of our first melanoma patient with a cell therapy to specifically target all cancer cells, marks a significant milestone in delivering the first precision TIL therapy.
  • Achilles uses its proprietary process to manufacture T cells (cNeT) which exquisitely target a specific set of clonal neoantigens in each patient.